Influence of triple disease modifying anti-rheumatic drug therapy on carotid artery inflammation in drug-naive patients with recent onset of rheumatoid arthritis.

scientific article published on 21 June 2016

Influence of triple disease modifying anti-rheumatic drug therapy on carotid artery inflammation in drug-naive patients with recent onset of rheumatoid arthritis. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1093/RHEUMATOLOGY/KEW240
P698PubMed publication ID27330160

P50authorJuhani KnuutiQ11867479
Jarna C. HannukainenQ43288538
Timo MöttönenQ59169124
Anna KirjavainenQ64438310
Antti SarasteQ96170801
Laura PiriläQ104135946
Matti HaavistoQ114563906
Anne RoivainenQ41091972
Kari K. KalliokoskiQ43235405
P2093author name stringJukka Kemppainen
Timo Yli-Kerttula
P2860cites workDo cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?Q45235877
(18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials.Q48904408
Performance of the new generation of whole-body PET/CT scanners: Discovery STE and Discovery VCT.Q50949090
Muscle-specific glucose and free fatty acid uptake after sprint interval and moderate-intensity training in healthy middle-aged men.Q51306531
2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiativeQ56506042
Measurement of patient outcome in arthritisQ56879288
The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisQ27860872
EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritisQ33505914
Optimizing 18F-FDG PET/CT imaging of vessel wall inflammation: the impact of 18F-FDG circulation time, injected dose, uptake parameters, and fasting blood glucose levels.Q33624365
PET in vasculitisQ33947065
Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against RheumatiQ34662758
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.Q34782898
The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis.Q35135831
Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control studyQ35605663
The advancing clinical impact of molecular imaging in CVD.Q37423120
Role of FDG-PET and PET/CT in the diagnosis and management of vasculitisQ37695932
Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time?Q37761792
Epidemiology of rheumatoid arthritis: rheumatoid arthritis and mortalityQ37774304
Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectivesQ37812524
Rheumatoid arthritis and cardiovascular diseaseQ38149252
Cardiovascular risk in rheumatoid arthritis: how to lower the risk?Q38152504
PET imaging of inflammation in atherosclerosisQ38218902
Relation of carotid artery 18F-FDG uptake to C-reactive protein and Framingham risk score in a large cohort of asymptomatic adultsQ38445305
An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapyQ39110166
Measurement of arterial activity on routine FDG PET/CT images improves prediction of risk of future CV eventsQ39309074
18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic diseaseQ39946694
Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendationsQ40091380
Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial groupQ41924053
Subclinical vasculitis as a potential mechanism to explain the heightened cardiovascular risk in rheumatoid arthritisQ42701584
P433issue10
P304page(s)1777-1785
P577publication date2016-06-21
P1433published inRheumatologyQ7320492
P1476titleInfluence of triple disease modifying anti-rheumatic drug therapy on carotid artery inflammation in drug-naive patients with recent onset of rheumatoid arthritis.
P478volume55

Reverse relations

cites work (P2860)
Q54202996Clinical Nononcologic Applications of PET/CT and PET/MRI in Musculoskeletal, Orthopedic, and Rheumatologic Imaging.
Q33678290Imaging atherosclerosis in rheumatoid arthritis: evidence for increased prevalence, altered phenotype and a link between systemic and localised plaque inflammation.

Search more.